If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) and wondered who is most vulnerable. The medical community has long recognized that certain patient characteristics—such as prior immunosuppressant use or longer treatment duration—can elevate PML risk. This guide explains the key risk factors and what the FDA's monitoring recommendations mean for patients.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn’s disease in adults. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefit when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML presents with a range of neurological symptoms that can include cognitive impairment, motor deficits, visual disturbances, and speech difficulties. The clinical presentation is often progressive, and diagnosis typically requires brain MRI and detection of JCV DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves the drug’s action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect in the brain can allow latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage. The FDA Adverse Event Reporting System (FAERS) database lists adverse events most frequently associated with Tysabri, including fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), malaise (7,319 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and depression (3,091 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the spectrum of neurological and systemic symptoms that may be associated with Tysabri use, some of which overlap with early PML manifestations.
For patients in Michigan who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability or medical malpractice claim. Michigan’s statute of limitations for personal injury actions is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For wrongful death claims, the period is typically three years from the date of death. Given that PML can have a delayed onset and progressive course, the timeline between Tysabri exposure and documented harm is critical. Patients may have received Tysabri for months or years before PML symptoms emerged, and diagnosis may be further delayed due to symptom overlap with MS. This latency period can affect when the statute of limitations begins to run. Adequacy of warnings is another key risk anchor. The Tysabri label includes a boxed warning and detailed precautions about PML risk, but questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the specific risk factors, and the need for vigilant monitoring. In Michigan, failure-to-warn claims require showing that the manufacturer did not provide sufficient information about known risks, and that this failure caused harm. The presence of the boxed warning and the TOUCH program may be relevant to such claims, but individual circumstances—such as whether a patient was tested for anti-JCV antibodies or informed about the significance of treatment duration—can influence the outcome. Patients affected by Tysabri-associated PML should consult with an attorney experienced in pharmaceutical litigation to assess their specific situation, including the date of diagnosis, the duration of Tysabri use, and any prior immunosuppressant exposure. Legal counsel can help determine whether the statute of limitations has been met and whether the warnings provided were adequate under Michigan law.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Michigan's statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For wrongful death claims, it is typically three years from the date of death. Because PML can have a delayed onset, the timeline between Tysabri exposure and diagnosis is critical in determining when the clock starts.
Three established risk factors are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefit when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.